Five Worst-Performing Stocks in 2024: What Investors Should Know

The stock market delivered impressive returns in 2024, with the S&P 500 climbing nearly 30% year-to-date through mid-December. Yet beneath this strong headline performance lies a starkly different story for several index components. Among the worst performing stocks in 2024, some declined by as much as 60%, dramatically lagging behind the benchmark. Understanding why these companies stumbled and what it means for investors is critical before considering any contrarian plays.

Why These S&P 500 Components Underperformed Significantly

Five stocks stand out as particularly weak performers during 2024:

Walgreens Boots Alliance (WBA) dropped 60.1%, facing severe headwinds from ecommerce disruption that has rapidly eroded its traditional retail business model.

Intel (INTC) declined 59.9%, struggling with competitive pressures in the semiconductor space and execution challenges that weighed on investor sentiment throughout the year.

Moderna (MRNA) fell 58.3%, grappling with disappointing vaccine sales revenues and an uncertain path toward sustainable growth in the coming years.

Celanese (CE) declined 55.2%, reflecting broader challenges within the chemical industry as economic uncertainty dampened demand.

Dollar Tree (DLTR) dropped 48.8%, contending with operational headwinds that pressured its retail operations and profit margins.

Data sourced from market tracking platforms and reflects performance through late 2024.

Understanding the Fundamental Issues Behind the Declines

Each of these worst performing stocks in 2024 faced distinct business challenges that drove their underperformance. These weren’t random declines—they reflected genuine deterioration in competitive position, revenue outlook, or market dynamics.

Walgreens exemplifies the structural headwind facing legacy retail: online competitors have systematically captured market share, forcing the company to adapt its business model while managing store closures and cost reductions. Similarly, Moderna’s stumble highlights the risks of revenue concentration in a single product category. When COVID-19 vaccine adoption stabilized, the company discovered its broader pipeline and commercial capabilities couldn’t offset the revenue cliff.

Intel’s situation reflects capital-intensive semiconductor competition. The company faced both manufacturing execution challenges and market share losses to competitors, creating a challenging valuation environment. Each company’s struggle serves as a reminder: steep discounts often exist for reasons.

Should You Buy the Dip? A Strategic Perspective

The critical question many investors ask when reviewing worst performing stocks is whether their current valuations represent genuine bargains or “value traps”—stocks that look cheap because the underlying business fundamentals remain broken.

The answer requires rigorous analysis. Yes, these companies could theoretically deliver exceptional returns if they successfully execute turnaround strategies. Several analysts maintain watchlists for potential recovery plays, believing management teams possess viable recovery plans. However, successful corporate turnarounds remain rare and difficult. Betting on one requires genuine conviction in both the strategy and the team executing it.

The cautionary tale of Nvidia illustrates the alternative perspective: when The Motley Fool’s analyst team identified Nvidia as a buy recommendation in April 2005, a $1,000 investment would have grown to approximately $853,765 by December 2024. This underscores the power of backing quality businesses trading at reasonable prices over catching falling knives with distressed companies.

Key Takeaways for Investors

Before deploying capital into worst performing stocks in 2024, remember that prices fell for substantive reasons. Cheap valuation alone doesn’t justify investment. Instead, conduct thorough due diligence on management’s recovery roadmap, competitive positioning, and the likelihood that the turnaround strategy will succeed.

Investors would be wise to maintain healthy skepticism about fallen angels. Sometimes deep value proves rewarding; other times it represents a value trap. The distinction hinges on your conviction that the underlying business can genuinely recover. Professional investors recognize this reality—which is why identifying high-quality companies at reasonable prices typically outperforms catching falling knives in distressed securities.

The worst performing stocks in 2024 warrant analysis, but not blind accumulation at current prices.